

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION April 14, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 0975.1005-010		APPLICATION NO. 09/766,535	
	FIRST NAMED INVENTOR Junming Le, <i>et al.</i>		FILING DATE January 18, 2001	
	EXAMINER K. A. Canella	CONFIRMATION NO. 1000	GROUP 1642	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
KAC	AL8	DE 42 02 665 A1	01/28/1992	Blitstein-Willinger	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AX12	Kassiotis, G. and Kollias, G., "Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (TNF) at the p55 TNF Receptor Level: Implications for Pathogenesis and Therapy of Autoimmune Demyelination," <i>J. of Exp. Med.</i> , 193(4):427-434 (2001).
KAC	AY12	Selmaj, K., <i>et al.</i> , "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination", <i>Ann. Neurol.</i> 30:694-700 (1991).
KAC	AZ12	Van Oosten, B. W., <i>et al.</i> , "Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2," <i>Neurology</i> , 47(6):1531-1534 (1996) Abstract.
KAC	AR13	Van Oosten, B. W., <i>et al.</i> , "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial," <i>Neurology</i> , 49(2):351-357 (1997) Abstract.
KAC	AS13	Arnason, B. G. W., <i>et al.</i> , "TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study," <i>Neurology</i> , 53(3):457-465 (1999) Abstract.

EXAMINER

DATE CONSIDERED